Dr. Reddy's Laboratories FY26 Annual Earnings Summary

Lenalidomide sales expected to drop significantly after Q2 FY26; magnitude depends on pricing and competitor behavior.

Canadian launch contingent on patent litigation outcome in India and FDA approval; any delay could push revenue to later quarters.

Rituximab BLA received a CRL; abatacept and semaglutide approvals face regulatory uncertainty.

Revlimid sales are declining faster than expected, with Q3 likely the last quarter of meaningful contribution.

Denosumab received CRL from FDA due to partner Alvotech's facility issues; Rituximab requires re-inspection. Both face delays of at least 6-12 months.

CEO advised to assume zero lenalidomide revenue from Q4 FY26, which will impact overall revenue and margins.

U.S. generics revenue has been flat despite new launches, indicating significant price erosion that may continue.

Base US business faces ongoing price erosion; management expects flat to single-digit growth but uncertainty remains.

SG&A at 30% of sales in Q1; management targets 28-29% for full year, but NRT and nutraceutical investments could keep it higher.

Multiple filers and potential compounding pharmacy entry could lead to aggressive pricing and lower margins.

Awaiting Delhi High Court decision; adverse ruling could delay India launch and impact export plans.

Management expects eventual competition in Canada and other markets, with pricing likely settling at lower end of $20-$70 range.